Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Pigment Cell Melanoma Res. 2018 Oct 22;32(2):292–302. doi: 10.1111/pcmr.12742

Figure 3: Major effects of statins are restricted to a limited number of pathways.

Figure 3:

(A). Human phospho-kinase antibody array profiling of lysates from resistant lines YUMACdr and YURIFdr treated with 5 μmol/L vemurafenib and 150nmol/L selumetinib with or without 5μmol/L simvastatin for 24 hours showing significant downregulation of AKT activation. (B), (C). Densitometric changes in AKT phosphorylation as measured by antibody array. Percent changes depicted with simvastatin treatment are relative to relevant control (DMSO only for Sim and VemSel only for VemSel+Sim).